Hims & Hers shares plunge 28% on concerns over weight loss business, margins
1. Q4 revenue nearly doubled; margins disappointed. Analysts missed 78.4% expectation. 2. Shares dropped 28% following results. Weight loss business concerns emerged. 3. GLP-1 offering generated over $225M in 2024. FDA semaglutide shortage resolved. 4. Strategic shift away from compounded semaglutide announced. Future weight loss products remain uncertain.